ZNTL
ZNTL news
Latest 2 stories · newest Jul 17, 2026
ZNTL
Zentalis announces Phase 1b MUIR trial data for azenosertib plus paclitaxel in ovarian cancer
Zentalis Pharmaceuticals presented Phase 1b MUIR trial results showing 39% overall response rate and 7.3-month median PFS for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients. The data demonstrates a manageable safety profile and supports continued development of az…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same ZNTL feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ZNTL/newsSTART FREE